Jounce Therapeutics (JNCE) began trading on Nasdaq on 27 Jan 2017

Massachusetts-based Jounce Therapeutics is a biopharmaceutical company developing cancer immunotherapy treatments.

• Company Website www.jouncetx.com
• CEO Richard Murray
• Employees (as of 12/31/2016) 85
• Fiscal Year End 12/31
• Status Priced (1/27/2017)
• Symbol JNCE
• Exchange NASDAQ Global Select

Share Price $16.00
Shares Offered 6,365,000
Offer Amount $101,840,000.00

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody.

Key stats and ratios

	Q1 (Mar '17)	2016
Net profit margin	1.90%	-36.84%
Operating margin	-1.22%	-38.89%
EBITD margin	-	-33.66%
Return on average assets	0.49%	-8.45%
Return on average equity	-2.90%	-
Employees	85

Scorecard of select recent IPOS

Company                             Symbol  Percent  Current  Offer  IPO Date*
AnaptysBio Inc.                         ANAB    23%      $18.50   $15.00 26-Jan-17
Kimbell Royalty Partners LP     KRP     14%      $20.52   $18.00 3-Feb-17
Keane Group Inc.                        FRAC    11%      $21.00   $19.00 20-Jan-17
Jounce Therapeutics Inc.            JNCE    10%      $17.57   $16.00 27-Jan-16
Trivago NV                              TRVG    4%       $11.49   $11.00 16-Dec-16
Invitation Homes Inc.               INVH    4%       $20.78   $20.00 1-Feb-17
Hebron Technology Co.           HEBT    2%       $4.07    $4.00  27-Dec-16
Jagged Peak Energy Inc.         JAG     -4%      $14.45   $15.00 27-Jan-16
Ramaco Resources Inc.           METC    -6%      $12.67   $13.50 3-Feb-17
ObsEva SA                               OBSV    -22%     $11.65   $15.00 26-Jan-17
 *Date represents first day of trading